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Introduction {#sec001}
============

Human African trypanosomiasis (HAT), also known as sleeping sickness, is one of the major neglected infectious diseases. Sleeping sickness is endemic in 36 African countries and over 60 million people are at risk of being infected \[[@pntd.0007603.ref001]\]. HAT is more prevalent in rural areas where health care is scarce and affects mainly individuals of reproductive age, increasing their poverty \[[@pntd.0007603.ref002]\].

HAT is a vector-borne parasitic disease transmitted by tsetse flies of the genus *Glossin*a. It is caused by two subspecies of the single-celled parasite *Trypanosoma brucei*: *T*.*b*. *rhodesiense* found in eastern and southern Africa, with reservoirs in livestock and wildlife, and *T*.*b*. *gambiense* found in central and western Africa, which causes the majority of human cases with the main reservoir being humans \[[@pntd.0007603.ref002],[@pntd.0007603.ref003]\]. Sleeping sickness has two clinical stages; the haemolymphatic stage followed by the meningoencephalitic stage. The two subspecies have different rates of disease progression; *T*.*b*. *rhodesiense* infection is typically described as an acute disease with rapid progression to late stage and *T*.*b*. *gambiense* progresses more slowly \[[@pntd.0007603.ref003]\].

Untreated HAT infections are believed to be 100% fatal, with death occurring within weeks or months of symptoms first appearing \[[@pntd.0007603.ref004],[@pntd.0007603.ref005]\]. However, there is increasing evidence that infection by *T*.*b*. *rhodesiense* can result in a wide range of clinical outcomes in its human host \[[@pntd.0007603.ref006]--[@pntd.0007603.ref008]\]. Furthermore, there is evidence that individuals from non-endemic areas suffer a more severe infection than people from endemic areas \[[@pntd.0007603.ref009],[@pntd.0007603.ref010]\]. Similar variation in disease progression is also observed in infections with *T*.*b*. *gambiense* \[[@pntd.0007603.ref011],[@pntd.0007603.ref012]\]. Some infected people in Guinea and Côte d'Ivoire progressed to self-cure after refusing treatment, and other individuals in endemic foci in West Africa have shown trypanotolerance analogous to that observed in some West African cattle breeds and in mouse models \[[@pntd.0007603.ref013]--[@pntd.0007603.ref018]\].

Genetic polymorphisms in *T*. *b*. *gambiense* as well as the human host have been shown to contribute to different responses to infection \[[@pntd.0007603.ref019]--[@pntd.0007603.ref021]\]. Genes involved in immune responses and regulating immunity play important roles in infection outcomes. One such gene is *Apo-lipoprotein-L1* (*APOL1*) whose variants G1 and G2 are associated with kidney disease in African Americans and have been predicted to have been selected because they provide protection against HAT \[[@pntd.0007603.ref022],[@pntd.0007603.ref023]\]. *APOL1* lyses trypanosomes by depolarizing the parasite lysosomal membrane, which leads to osmotic swelling and rupture of the lysosome and then lysis of the trypanosome \[[@pntd.0007603.ref024]--[@pntd.0007603.ref028]\]. *Trypanosoma brucei rhodesiense* can infect humans because they express the serum-resistance-associated (*SRA*) protein, which binds to the *SRA*-interacting domain of *APOL1* resulting in the loss of *APOL1* lytic function \[[@pntd.0007603.ref024]--[@pntd.0007603.ref030]\]. It has been shown that serum containing G1 and G2 alleles of *APOL1* is lytic to *T*.*b*. *rhodesiense in vitro*, whilst the parasites are resistant to serum containing the G0 allele \[[@pntd.0007603.ref022]\], but evidence that these alleles of *APOL1* mediate resistance to parasites *in vivo* is less conclusive. The G2 allele has been associated with protection against *T*.*b*. *rhodesiense* HAT in one study in Uganda but not in another, and no associations have been found between carriage of the G1 allele and reduced risk of developing *T*.*b*. *rhodesiense* HAT \[[@pntd.0007603.ref031],[@pntd.0007603.ref032]\].

Other genes have also been implicated in the response to infection with *T*. *brucei spp*. Two candidate gene association studies in the Democratic Republic of Congo (DRC) have shown association with the disease and alleles of four genes *(IL6*, *HLA-G*, *IL10* and *APOL1)* out of the 10 genes (*IL1A*, *IL4*, *IL6*, *IL8*, *IL10*, *TNFA*, *IFNG*, *HLA-G*, *HPR* and *APOL1)* studied \[[@pntd.0007603.ref021],[@pntd.0007603.ref033]\]. In other studies, cytokine levels have shown significant association with HAT infections, but the genetic factors regulating this response have not been identified \[[@pntd.0007603.ref008],[@pntd.0007603.ref033]--[@pntd.0007603.ref037]\]. In the present study, we investigated the role of single nucleotide polymorphisms in 17 genes (*IL10*, *IL8*, *IL4*, *HLA-G*, *TNFA*, *IL6*, *IFNG*, *MIF*, *APOL1 HLA-A*, *IL1B*, *IL4R*, *IL12B*, *IL12R*, *HP*, *HPR* and *CFH*) for association with susceptibility to HAT using a case-control study design on subjects from the northern part of Malawi.

Materials and methods {#sec002}
=====================

Population and study design {#sec003}
---------------------------

The samples came from the Rumphi District in northern Malawi ([Fig 1](#pntd.0007603.g001){ref-type="fig"}), where the prevalence of HAT cases is highest in Malawi. Between 2000 and 2006, 150 people were confirmed to have died of HAT in Rumphi district alone \[[@pntd.0007603.ref038],[@pntd.0007603.ref039]\].

![Map of Malawi showing Rumphi District.](pntd.0007603.g001){#pntd.0007603.g001}

Cases were identified through active and passive surveys. Hospital case files were checked for previously diagnosed HAT patients and were followed up in their communities. All these cases had been treated with Suramin I.V 20 mg/kg body weight for 23 days and Melarsoprol I.V 3.6 mg/kg body weight for 23 days for the early and late stage of HAT respectively according to Malawi HAT Treatment Guidelines [S1 Table](#pntd.0007603.s005){ref-type="supplementary-material"}. They were then followed up at 3, 6, and 12 months after discharge for review [S1 Table](#pntd.0007603.s005){ref-type="supplementary-material"}. The active screening was conducted during the follow-up of HAT cases. After taking a history and an examination related to HAT infection, venous blood was collected in heparinized tubes and taken to the laboratory at a temperature of 4°C. Eight capillary tubes were prepared from each sample and the buffy coat was examined by microscopy. Out of 350 people screened, 243 individuals entered the study \[[@pntd.0007603.ref040]\]. Cases were defined as individuals in whom trypanosomes were detected by microscopy in blood, lymphatic fluid or cerebral spinal fluids (CSF). Controls were defined as individuals with no signs and symptoms suggestive of HAT and no trypanosomes detected from the blood.

A total of 202 samples, 70 cases and 132 controls were genotyped. Cases and controls came from the same area, were born in the area and had been exposed to infection since birth.

Ethics statement {#sec004}
----------------

The protocol was approved by the Malawi National Health Sciences Research Committee, protocol numbers **NHSRC 15/4/1399** and **Malawi 1213**. There was also local involvement of all stakeholders, and local leaders gave approval for the study to be carried out in the area. All individuals enrolled in the study were 18 years of age or older. All individuals signed informed consent forms in their native language.

Power analysis {#sec005}
--------------

This study was one of six studies of populations of HAT endemic areas in Cameroon, Cote d'Ivoire, Guinea, Malawi, Democratic Republic of Congo (DRC), and Uganda. The studies were designed to have: 80% power to detect odds ratios (OR) \>2 for loci with disease allele frequencies of 0.15--0.65; and 100 cases; 100 controls with the 96 SNPs genotyped.

This study had 132 controls, 70 cases from our study area, and had 80% power to detect an OR \>2 with disease allele frequencies of 0.1--0.75 with the 96 SNPs genotyped. Power calculations were undertaken using the genetics analysis package gap in R \[[@pntd.0007603.ref041]--[@pntd.0007603.ref043]\].

DNA extraction {#sec006}
--------------

DNA was extracted from whole blood (collected in heparin vacutainer tubes (BD) during survey), using Qiagen DNeasy Blood & Tissue Kit (Crawley, UK) as per the manufacturer's instructions. Extracted DNA samples were temporarily stored at -20°C.

Genes selection {#sec007}
---------------

Genes were selected based on prior knowledge of their role in the development of HAT. The following genes were selected: *IL10*, *IL8*, *IL4*, *HLAG*, *TNFA*, *IL6*, *IFNG*, *MIF*, *APOL*, *HLAA*, *IL1B*, *IL4R*, *IL12B*, *IL12R*, *HP*, *HPR*, and *CFH* \[[@pntd.0007603.ref020]--[@pntd.0007603.ref022],[@pntd.0007603.ref031],[@pntd.0007603.ref033],[@pntd.0007603.ref036],[@pntd.0007603.ref044]--[@pntd.0007603.ref053]\].

SNP selection {#sec008}
-------------

Ninety-six SNPs were selected for genotyping using two strategies: 1) SNPs that had been previously reported to be associated with HAT or 2) by scanning for sets of linked marker SNP (r^2^ \<0.5) across each of *IL4*, *IL8*, *IL6*, *HLAG*, *MIF* and *IFNG*. The SNPs in this second group of genes were selected using a merged SNP dataset obtained from low fold coverage (8-10x) whole genome shotgun data generated from 230 residents living in regions (DRC, Guinea Conakry, Ivory Coast and Uganda) where trypanosomiasis is endemic (TrypanoGEN consortium, sequences at European Nucleotide Archive Study: EGAS00001002602) and 1000 Genomes Project data from African populations \[[@pntd.0007603.ref054]\]. PLINK v1.9 package (<https://www.cog-genomics.org/plink/1.9/>) \[[@pntd.0007603.ref055]\] was used to estimate linkage disequilibrium (LD) (r^2^) between loci and all sets of SNPs covering the gene were identified. Loci that were excluded during assay development or failed to be genotyped were not replaced and hence not all regions of each gene were linked to marker SNP. [S2 Table](#pntd.0007603.s006){ref-type="supplementary-material"} shows the candidate genes and SNPs selected for this study.

SNP genotyping {#sec009}
--------------

Samples were genotyped by two commercial service providers: INRA- Site de Pierroton, Plateforme Genome Transcriptome de Bordeaux, France and LGC Genomics, Hoddesden, UK. At INRA, two sets of 40 SNP assays were designed using Assay Design Suite v2.0 (Agena Biosciences). SNPs were genotyped with the iPLEX Gold genotyping kit (Agena Biosciences) for the MassArray iPLEX genotyping assay, following the manufacturer's instructions. Products were detected on a MassArray mass spectrophotometer and data were acquired in real time with MassArray RT software (Agena Biosciences). SNP clustering and validation was carried out with Typer 4.0 software (Agena Biosciences). LGC Genomics genotyped all SNPs that failed genotyping at INRA and some additional SNPs using the PCR based KASP assay \[[@pntd.0007603.ref056]\].

Data analysis {#sec010}
-------------

Plink 1.9 \[[@pntd.0007603.ref055]\] was used for data analysis and R version 3.3.1 (2016-06-21)---\"Bug in Your Hair\" was used for data visualization (R Foundation for Statistical Computing, Vienna Austria). The data from genotyping were converted to PLINK format and were tested for data completeness, allele frequencies, LD, and Hardy-Weinberg equilibrium (HWE). Individuals and SNP loci with more than 15% and 20% missing data respectively, were removed from the analysis. Fisher's exact test \[[@pntd.0007603.ref057]\] in PLINK was used for testing the association of SNPs with HAT. One of each pair of SNPs with post genotyping linkage r^2^ \> 0.5 were excluded. This increased the power of analysis by reducing the number of tests. Multiple testing was corrected for using a Bonferroni corrected p-value of 0.00077 (0.05/65) \[[@pntd.0007603.ref058]\] and the Benjamini Hochberg false discovery rate (FDR) was used to estimate the probability that the null hypothesis of no association should not be rejected \[[@pntd.0007603.ref058],[@pntd.0007603.ref059]\].

Results {#sec011}
=======

Two hundred and two samples were sent for genotyping. There were 143 males (70%) and 59 females (30%) with 70 cases (35%) and 132 (65%) controls. The mean ages of the cases and controls were 45 and 41 respectively.

Ninety-six SNPs were genotyped from 17 genes (see **Plink MAP** and **PED files** [S1](#pntd.0007603.s001){ref-type="supplementary-material"} and [S2](#pntd.0007603.s002){ref-type="supplementary-material"} Data). After the data was cleaned, 26 individuals with more than 15% missing data were filtered out leaving 176; 59 cases and 117 controls. Nine SNPs with more than 20% missing data were filtered out leaving 87 (see [S1](#pntd.0007603.s003){ref-type="supplementary-material"} and [S2](#pntd.0007603.s004){ref-type="supplementary-material"} Figs). Four SNPs, which were not in HWE, were removed. A cut-off of HWE p-value of 1 x 10−8 was used and genotype scatter plots were checked for allele clusters.

To increase the power of analysis, 18 SNPs, which were linked to each other (r^2^ \> 0.5), were excluded by pruning (by working across the loci in windows of five SNPs moving one SNP at a time and excluding one of each pair of SNPs with LD greater than r^2^ = 0.5). After quality control and linkage pruning, 65 SNPs were left for association analysis. See [S3 Table](#pntd.0007603.s007){ref-type="supplementary-material"} showing filtered data, and [S4 Table](#pntd.0007603.s008){ref-type="supplementary-material"} showing pruned SNPs.

Results of case-control studies can be confounded by population structure. Most of the cases and controls (95%) were Tumbuka speakers, however there were speakers of five other languages in the cases (3) and controls (8) ([Table 1](#pntd.0007603.t001){ref-type="table"}). If the minor language speakers had different allele frequencies from the Tumbuka, this could affect the results.

10.1371/journal.pntd.0007603.t001

###### Numbers of speakers of each language represented in the sample.

![](pntd.0007603.t001){#pntd.0007603.t001g}

  Language   Cases   Controls   Total
  ---------- ------- ---------- -------
  Tumbuka    67      124        191
  Chewa      1       4          5
  Senga      1       0          1
  Ngoni      1       2          3
  Sena       0       1          1
  Lomwe      0       1          1
  Total      70      132        202

Association study {#sec012}
-----------------

The Fisher's exact test was used to compare allele frequencies in cases and controls. Allele frequencies differed at two SNPs in two genes (*APOL1* and *IL6*) between the cases and controls. However, only rs71785313 (G2) in *APOL1* (OR 0.14) remained significant after Bonferroni correction (threshold p = 0.00077) and after Benjamini-Hochberg FDR correction, as shown in [Table 2](#pntd.0007603.t002){ref-type="table"}. Complete results for all loci are shown in [S5 Table](#pntd.0007603.s009){ref-type="supplementary-material"}. The data was also analysed using logistic regression with gender and age as covariates, neither of these covariates had significant effects (p \> 0.05) (see [S6 Table](#pntd.0007603.s010){ref-type="supplementary-material"}).

10.1371/journal.pntd.0007603.t002

###### Association analysis between HAT cases and controls showing SNPs with lowest p-Values and SNPs in APOL1 gene.

![](pntd.0007603.t002){#pntd.0007603.t002g}

  CHR   SNP          GENE       BP         A1    F_A       F_U       A2    P                                                 OR       L95    U95    p(HWE)   BONF       FDR_BH
  ----- ------------ ---------- ---------- ----- --------- --------- ----- ------------------------------------------------- -------- ------ ------ -------- ---------- ----------
  22    rs71785313   APOL1_G2   36662046   DEL   0.0339    0.1974    INS   1.05E-05[\*\*](#t002fn003){ref-type="table-fn"}   0.1427   0.05   0.41   1        0.000685   0.000685
  7     rs2069845    IL6        22770149   G     0.2458    0.3491    A     0.04512[\*](#t002fn002){ref-type="table-fn"}      0.6074   0.37   1.0    0.8378   1          0.9519
  22    rs136177     APOL1      36661842   G     0.06034   0.03947   A     0.3508                                            1.563    0.57   4.3    1        1          0.9519
  22    rs73885319   APOL1_G1   36661906   G     0.1271    0.1207    A     0.7977                                            1.061    0.54   2.07   1        1          0.9519
  22    rs73885316   APOL1      36661674   A     0.01695   0.01293   C     0.8333                                            1.316    0.22   7.99   1        1          0.9519
  22    rs136174     APOL1      36661536   C     0.02586   0.02212   A     0.8607                                            1.173    0.28   5.00   1        1          0.9519

Analysis of loci within *APOL1* and *IL6* for association with HAT. CHR: Chromosome number, SNP: single nucleotide polymorphism dbSNP id, BP: Physical position (base-pair in GRCh37), A1: Minor allele, A2: Major allele, F_A: Frequency of allele 1 in cases, F_U: Frequency of allele 1 in controls, P: Exact p-value, BONF: Bonferroni corrected p-value, FDR_BH: false discovery rate, OR: Estimated odds ratio (for A1), CI95: 95% confidence interval of odds ratio, HWE: Hardy-Weinberg Equilibrium p-value

\* P-value significant

\*\* Bonferroni correction significan**t**

An association was observed at *APOL1*\_*G2* rs71785313 ([Table 2](#pntd.0007603.t002){ref-type="table"}) with an odds ratio of 0.14 (95% CI: 0.05 to 0.41, p = 0.00001). This indicates a substantially reduced susceptibility to *T*.*b*. *rhodesiense* infection for individuals that possess a G2 variant. No association was found at *APOL1 G1* rs73885319 with *T*.*b*. *rhodesiense* infection (p = 0.80; [Table 2](#pntd.0007603.t002){ref-type="table"}). The remaining 15 genes did not show any statistically significant difference in the allele frequencies between cases and controls as shown in [S5 Table](#pntd.0007603.s009){ref-type="supplementary-material"}.

Discussion {#sec013}
==========

The study looked at 96 SNPs in seventeen genes to test genetic association with HAT in the northern part of Malawi. The main finding of this study is that the *APOL1* G2 variant was strongly associated with protection against *T*.*b*. *rhodesiense* infection in northern Malawi. This is the first study to show such an association in Malawi. Our study showed a seven-fold reduced susceptibility for individuals possessing the *APOL1* G2 variant. This is consistent with a two-centre study in Uganda and Guinea \[[@pntd.0007603.ref031]\] that found a five-fold reduced susceptibility to *T*.*b*. *rhodesiense* for individuals that possess a single copy of G2 variant but no association with the G1 haplotype and *T*.*b*. *rhodesiense*. However, another study in Uganda found no association between the G2 allele and *T*.*b*. *rhodesiense* HAT \[[@pntd.0007603.ref032]\]. The two studies in Uganda were conducted in two very different populations. Cooper et al. \[[@pntd.0007603.ref031]\] found an association in a population from Kabermaido District of mixed Nilotic and Bantu descent with a *G2* allele frequency in controls of 14.4%, whereas Kimuda and colleagues \[[@pntd.0007603.ref032]\] found no association in a population of Bantu descent in Busoga district with a G2 frequency of 8.6%. The *G2* frequency in this study was 19.7% ([Table 2](#pntd.0007603.t002){ref-type="table"}), which is comparable to that in the Kabermaido population in Uganda. However, the Malawi population is also of Bantu descent and is linguistically and possibly genetically closer to the Busoga population with low G2 frequency and no association with HAT. Thus, G2 frequencies and association between G2 and HAT do not correlate with the major ethno-linguistic groups. This discrepancy may be due to random genetic drift or specific selection by HAT and/or other diseases at this locus or to variation in the *SRA* gene in the different foci.

There was no association between the G1 allele and HAT in Malawi, which is consistent with both previous studies on *T*.*b*. *rhodesiense* HAT in Uganda \[[@pntd.0007603.ref031],[@pntd.0007603.ref032]\], but this is in contrast to studies of *T*.*b*. *gambiense* HAT population in Guinea where the G1 allele was protective \[[@pntd.0007603.ref031],[@pntd.0007603.ref060]\]. An *in vitro* study also showed that G1 alleles are associated with less lytic potential than G2 alleles \[[@pntd.0007603.ref022]\].

The seven-fold reduced susceptibility for individuals with *APOL1* G2 variant is consistent with the *in vitro* evidence of lysis of *T*.*b*. *rhodesiense* by plasma containing the *APOL1* G2 allele and a study that showed that mice with *APOL1* G2 survived longer after infection with *T*.*b*. *rhodesiense* \[[@pntd.0007603.ref022],[@pntd.0007603.ref061]\]. Both the G1 and G2 renal risk variants are in the *SRA*-interacting domain of *APOL1*. The two-amino acid deletion in G2 rs71785313 prevents the binding of *SRA* to *APOL1* \[[@pntd.0007603.ref022],[@pntd.0007603.ref061],[@pntd.0007603.ref062]\], enabling carriers of the G2 variant to lyse the parasites.

The G1 haplotype consists of two missense mutations in almost perfect linkage disequilibrium (rs73885319 and rs60910145). In this study, only rs73885319 was genotyped ([Table 2](#pntd.0007603.t002){ref-type="table"} and [S2 Table](#pntd.0007603.s006){ref-type="supplementary-material"}), but no association was found with HAT in Malawi.

In conclusion, this study has shown that host genetic polymorphisms play a role in the control of infections and morbidity in HAT. Of the 17 genes studied, only the *APOL1* G2 variant showed a statistically significant association with *T*. *b*. *rhodesiense* infections after Bonferroni correction for multiple testing. This is the first study in Malawi to show this association and increases support for a role for this allele in disease resistance which has previously been found associated in one study but not associated in another study. Further studies will be required to determine the effect of the G1 variant on the severity of *T*. *b*. *rhodesiense* infections and gene expression between the cases and the controls.
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